Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh(Saarland University), Jöerg Schubert(Saarland University), Marita Ziepert(Leipzig University), Rudolf Schmits(Saarland University), Martin Mohren(University Hospital Magdeburg), Eva Lengfelder(University Hospital Heidelberg), Marcel Reiser(University Hospital Cologne), Christina Nickenig(Ludwig-Maximilians-Universität München), Michael Clemens(Klinikum Mutterhaus der Borromäerinnen), Norma Peter(Carl-Thiem-Klinikum Cottbus), Carsten Bokemeyer(University Medical Center Hamburg-Eppendorf), Hartmut Eimermacher(St. Marien Hospital), Anthony D. Ho(University Hospital Heidelberg), Martin Hoffmann(Klinikum Ludwigshafen), Roland Mertelsmann(University Medical Center Freiburg), Lorenz Trümper(University of Göttingen), Leopold Balleisen(Evangelisches Krankenhaus Hamm), Rüediger Liersch(University Hospital Münster), Bernd Metzner(Klinikum Oldenburg), Frank Hartmann(Saarland University), Bertram Glaß(University of Göttingen), Viola Poeschel(Saarland University), Norbert Schmitz(Asklepios Klinik St. Georg), Christian Ruebe(Saarland University), Alfred C. Feller(University of Lübeck), Markus Loeffler(Leipzig University)
Cited by 1,134
Abstract
Related Papers
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The International Non-Hodgkin's Lymphoma Prognostic Factors Project|New England Journal of Medicine|1993|5k